ChatDOC/OCRFlux-bench-single huggingface dataset:
2
VM (×10−8 s2 )m	6 \( \pm \) 0.5
f11 (V)	1.11 \( ^ + \) 0.05
f12 (V)	−1.30 ± 0.05
f44 (V)	−0.28 ± 0.05
\( f _ { 1 1 } ^ { \mathrm { t o t } } \)(V)	−2.1 ± 0.1
\( f _ { 1 2 } ^ { \mathrm { t o t } } \)(V)	−2.5 ± 0.1
tot \( I A \)
(V)
4	−1.5 ± 0.1
χ/0	2400

TABLE I. Calculated static (f), dynamic (M), and total (\( f ^ { \mathrm { t o t } } \)) flexocoupling coefficients for cubic \( \mathrm { S r T i O 3 } \) (\( a \) = 3.886 ˚A) under a pressure of 78 kBar using dynamical matrix. \( \chi / \epsilon _ { 0 } \) is the relative dielectric susceptibility.

(11N
10 2 )m	(a) Dyn. mat.	(b) Ph. dis.p	(c) Ex.p
c11	2.77 ± 0.05	3.1 \( \pm \) 0.1	3.16
c12	1.06 ± 0.05	0.9 \( \pm \) 0.1	1.03
c44	0.92 \( + \) 0.05	1.0 \( \pm \) 0.1	1.22
|M|c44
(V)ρ	1.2 \( \pm \) 0.1	1.1 \( \pm \) 0.4
|ftotV44 | ()	1.5 \( + \) 0.1	1.5 \( \pm \) 0.2	1.2-2.2
|ftottt− V11 fo12 | ()	0.2 \( \pm \) 0.1	\( < \) 0.5	1.2-1.4

TABLE II. Material parameters for cubic \( \mathrm { { S r T i O } _ { 3 } } \) (\( a \) = 3.886 ˚A) under a pressure of 78 kBar obtained using the dynamical matrix and from analysis of phonon dispersion curves. c is the stiffness tensor. \( f ^ { \mathrm { t o t } } \) is defined in Eq. (20). \( \rho \) is the density \( ( \rho = 5 1 7 4 \frac { \mathrm { k g } } { \mathrm { m } ^ { 3 } } ) \)) calculated by the mass of atoms in the unit cell divided by the cell volume. (a) Calculated from dynamical matrix. (b) Obtained from the simulated phonon dispersion curves. (c) Obtained from the experimental phonon dispersion curves [17–19].

verse optic (TO) branches for the high symmetry [100], [110], and [111] directions of wavevec-tor. In this case, the phonons are not accompanied by any wave of the electric field and the continuum theory equations, Eqs. (1) and (2) with \( E _ { i } = 0 \), yield the following dispersion equation for the frequency \( \omega \) of the transverse modes [6]:
The excess over the par value for the 291,833,279 ordinary shares issued was credited to the share premium account with aggregate amount of approximately RMB4,464,387,000.

(c) In February 2016, 33,010,341 ordinary shares of the Company were allotted and issued to an entity controlled by Tencent and a number of independent third parties at a price of US\$3.0294 per share for an aggregated consideration of approximately US\$100,000,000 (equivalent to approximately RMB652,445,000). These shares rank pari passu in all respects with the shares in issue.

The excess over the par value for the 33,010,341 ordinary shares issued was credited to the share premium account with aggregate amounts of approximately RMB652,423,000.

(d) In January 2017, 30,201,818 ordinary shares of the Company were allotted and issued to three existing shareholders of the Company at a price of US\$3.31 per share for an aggregated consideration of approximately US\$100,000,000 (equivalent to approximately RMB 687,765,000). These shares rank pari passu in all respects with the shares in issue. The excess over the par value for the 30,201,818 ordinary shares issued was credited to the share premium account with aggregate amount of approximately RMB687,744,000.

# 36 Other reserves

# Group

Contribution
from holding
company	Currency
translation
differences	Put option
on non-
controlling
interests	Share-based
compensation
reserve	Statutory
surlpus
reserve fund	Total
RMB’000	RMB’000	RMB’000	RMB’000	RMB’000	RMB’000
As at January 1, 2014 .....	1,613	—	—	—	—	1,613
Deemed contribution .......	18,314	—	—	—	—	18,314
Currency translation
differences ..................	—	(595)	—	—	—	(595)
Share-based compensation
expenses (Note 37) ......	3,319	—	—	3,259	—	6,578
Profit appropriations to
statutory reserves
(Note a) ......................	—	—	—	—	517	517
Others .............................	768	—	—	—	—	768
Initial recognition of put
option liability ............	—	—	(65,396)	—	—	(65,396)
As at December 31, 2014	24,014	(595)	(65,396)	3,259	517	(38,201)
As at January 1, 2015 .....	24,014	(595)	(65,396)	3,259	517	(38,201)
Currency translation
differences ..................	—	(9,571)	—	—	—	(9,571)
Share-based compensation
expenses (Note 37) ......	1,081	—	—	130,705	—	131,786
Profit appropriations to
statutory reserves
(Note a) ......................	—	—	—	—	8,863	8,863
Others .............................	1,686	—	—	—	—	1,686
As at December 31, 2015	26,781	(10,166)	(65,396)	133,964	9,380	94,563
Contribution
from holding
company	Currency
translation
differences	Put option
on non-
controling
interests	Share-based
compensation
reserve	Statutory
surlpus
reserve
fund	Cailpta
reserve	Total
RMB’000	RMB’000	RMB’000	RMB’000	RMB’000	RMB’000	RMB’000
As at January 1, 2016	26,781	(10,166)	(65,396)	133,964	9,380	—	94,563
Currency translation
differences ..............	—	27,229	—	—	—	—	27,229
Share-based
compensation
expenses (Note 37) .	585	—	—	77,438	—	—	78,023
Acquisition of
non-controlling
interests (Note b) ....	—	—	—	—	—	(7,281)	(7,281)
Profit appropriations
to statutory reserves
(Note a) ..................	—	—	—	—	14,686	—	14,686
Others ........................	3,658	—	—	—	—	—	3,658
As at December 31,
2016 .......................	31,024	17,063	(65,396)	211,402	24,066	(7,281)	210,878
(Unaudited)
As at January 1, 2016	26,781	(10,166)	(65,396)	133,964	9,380	—	94,563
Currency translation
differences ..............	—	5,545	—	—	—	—	5,545
Share-based
compensation
expenses (Note 37) .	151	—	—	39,008	—	—	39,159
Acquisition of
non-controlling
interests (Note b) ....	—	—	—	—	—	(7,281)	(7,281)
Others ........................	730	—	—	—	—	—	730
As at June 30, 2016 ...	27,662	(4,621)	(65,396)	172,972	9,380	(7,281)	132,716
As at January 1, 2017	31,024	17,063	(65,396)	211,402	24,066	(7,281)	210,878
Currency translation
differences ..............	—	(21,835)	—	—	—	—	(21,835)
Share-based
compensation
expenses (Note 37) .	305	—	—	52,295	—	—	52,600
Others ........................	2,295	—	—	—	—	—	2,295
As at June 30, 2017 ...	33,624	(4,772)	(65,396)	263,697	24,066	(7,281)	243,938
No.	Project Names	City	Interest
Attributable to
the Group	Primary Intended
Use	Site Area
(sq.m.)	Actual/
Estimated
Completion
Date	Land
Bank(1)
(sq.m.)	Address
34.	Zhumadian Royal Lantai
Mansion Phase V	Zhumadian	70%	Residential/
Commercial/
Carpark/Ancillary/
Others	156,270	2023/8/1	388,318	The southeast side of
the intersection of
Lizhuang Road and
Chunliu Road, and the
northwest side of the
intersection of Zhangtai
Road and Jianshe
Avenue, Zhumadian
City, Henan Province
35.	Jingzhou Leading Lantai
House	Jingzhou	100%	Residential/
Commercial/
Carpark/Ancillary/
Others	54,070	2021/12/31	208,275	Northwest of the
intersection of Chutian
Road and Dongqiao
Road, Jingbei New
District, Jingzhou
District, Jingzhou City,
Hubei Province
36.	Jingzhou Leading
Fengming Lantai
Mansion	Jingzhou	100%	Residential/
Commercial/
Carpark/Ancillary/
Others	48,399	2022/8/31	188,088	No.66, Fengming Avenue,
Jingzhou District,
Jingzhou City, Hubei
Province
37.	Leshan Amazon	Leshan	100%	Residential/
Commercial/
Carpark/Ancillary	91,900	2014/10/16	2,571	No. 418 and No. 424,
North Section of
Longyou Road,
Shizhong District,
Leshan City, Sichuan
Province
38.	Leshan Haina Mansion	Leshan	51%	Residential/
Commercial/
Carpark/Ancillary/
Others	36,200	2016/1/5	6,904	No.1589 Muyuan Road,
Muchuan County,
Leshan City, Sichuan
Province
39.	Leshan Lantai House	Leshan	60%	Residential/
Commercial/
Carpark/Ancillary/
Others	88,108	2021/12/31	156,422	East of the intersection
of Sansu Road and
Ruixiang Road,
Qingjiang New District,
Shizhong District,
Leshan City, Sichuan
Province
40.	Leshan Tianyu	Leshan	100%	Residential/
Commercial/
Carpark/Ancillary	29,796	2020/3/1	14,033	Intersection of Hanlin
Road and Fenghuang
Road, Tongjiang
District, Leshan City,
Sichuan Province
No.	Project Names	City	Interest
Attributable to
the Group	Primary Intended
Use	Site Area
(sq.m.)	Actual/
Estimated
Completion
Date	Land
Bank(1)
(sq.m.)	Address
41.	Leshan Lanshan	Leshan	70%	Residential/
Commercial/
Carpark/Ancillary/
Others	89,630	2021/10/1	155,006	No. 881, Section 1,
Ruixiang Road, Leshan
City, Sichuan Province
42.	Leshan International
Mansion	Leshan	100%	Residential/
Commercial/
Carpark/Ancillary/
Others	127,204	2019/5/17	3,568	Taoyuan New Village,
Mouzi Town, Shizhong
District, Leshan City,
Sichuan Province
43.	Zunyi Lantai House	Zunyi	55%	Residential/
Commercial/
Carpark/Ancillary/
Others	39,759	2022/11/30	130,977	Intersection of Shanghai
Road and Ningbo
Road, Huichuan
District, Zunyi City,
Guizhou Province
44.	Meishan Triumph
International Mansion	Meishan	100%	Residential/
Commercial/
Carpark/Ancillary/
Others	256,303	2020/11/27	57,506	Southwest corner of the
intersection of Hubin
Road and Meizhou
Avenue, Meishan City,
Sichuan Province
45.	Meishan Triumph Square	Meishan	79%	Residential/
Commercial/
Carpark/Ancillary	73,976	2015/5/19	17,092	Northeast of the
intersection of Suyuan
Road and Dongpo
Avenue, Dongpo
District, Meishan City,
Sichuan Province
46.	Meishan Huayu Phase II	Meishan	60%	Residential/
Commercial/
Carpark/Ancillary/
Others	9,102	2020/6/3	5,568	Southeast corner of the
intersection of Suyuan
Road and Chongguang
Street, Meishan City,
Sichuan Province
47.	Meishan Triumph
International Mansion
Phase II	Meishan	57%	Residential/
Commercial/
Carpark/Ancillary/
Others	39,838	2019/7/30	8,744	Northeast of the
intersection of
Jiangxiang Road and
Qingyihang, Dongpo
District, Meishan City,
Sichuan Province
48.	Meishan Lantai House	Meishan	55%	Residential/
Commercial/
Carpark/Ancillary/
Others	109,814	2022/12/10	369,014	Northwest corner of the
intersection of Fucheng
Road and Shuangfeng
Street, Dongpo District,
Meishan City, Sichuan
Province
Notes	2020	2019
HK$’000	HK$’000
ASSETS AND LIABILITIES
Non-current assets
Property, plant and equipment	13	110,439	4,229
Intangible asset	14	87	1,027
Deposit paid for acquisition for intangible asset	16	1,000	–
111,526	5,256
Current assets
Inventories	15	7,360	7,383
Trade and other receivables	16	3,641	4,753
Tax refundable	869	899
Time deposits	17	11,007	16,000
Cash and bank balances	5,798	10,172
28,675	39,207
Current liabilities
Trade and other payables	18	1,052	1,486
Bank borrowings	19	12,250	–
Lease liabilities	21	511	–
13,813	1,486
Net current assets	14,862	37,721
Total assets less current liabilities	126,388	42,977
Notes	2020	2019
HK$’000	HK$’000
Non-current liabilities
Provision for long service payment	608	476
Provision for reinstatement cost	854	1,269
Bank borrowings	19	42,750	–
Promissory notes	20	44,724	–
Lease liabilities	21	940	–
89,876	1,745
Net assets	36,512	41,232
Equity
Share capital	22	41,879	41,879
Reserves	(5,367)	(647)
Total equity	36,512	41,232

Chan Kun Yuen	Chan Shu Yuen
Director	Director

The notes on pages 74 to 130 are an integral part of these consolidated financial statements.
# 35 Subsequent event

On 15 March 2019, a subsidiary of the Group entered into an agreement to fully dispose of its equity interest, representing 50% equity interest, in Shanghai Kaitai, a joint venture of the Group, to the joint venture partner of Shanghai Kaitai at a consideration of RMB1,005 million. Shanghai Kaitai has completed the development of its real estate project and distributed the profit to its respective shareholders before the disposal. The consideration was determined in accordance with the appraised net assets value of Shanghai Kaitai as of 31 January 2019. The transaction is expected to be completed by the end of March 2019.

# 36 Balance sheet of the Company

As at 31 December
2018	2017
RMB’000	RMB’000
ASSETS
Non-current assets
Interests in a subsidiary	2,016,724	1,993,141
Financial assets at fair value through profit or loss	649,860	—
2,666,584	1,993,141
Current assets
Prepayments and other receivables	208	1,296
Amounts due from subsidiaries	7,679,814	6,654,600
Amounts due from a related party	637,433	—
Cash and bank balances	30,610	49,585
Total current assets	8,348,065	6,705,481
Total assets	11,014,649	8,698,622
EQUITY
Equity attributable to owners of the Company
Share capital	14	13
Share premium	4,423,556	3,506,038
Other reserves	(1,363,382)	(169,894)
Total equity	3,060,188	3,336,157
# 36 Balance sheet of the Company (continued)

As at 31 December
2018	2017
RMB’000	RMB’000
LIABILITIES
Non-current liabilities
Borrowings	5,286,770	197,013
Current liabilities
Borrowings	2,393,994	5,114,757
Other payables	257,259	50,695
Amounts due to related parties	16,438	—
Total current liabilities	2,667,691	5,165,452
Total liabilities	7,954,461	5,362,465
Total equity and liabilities	11,014,649	8,698,622

Other reserve of the Company included share-based compensation reserve and accumulated losses. During the year, the change in share-based compensation reserve represents mainly the value of employee services under the share option scheme amounting to RMB23,583,000 (2017: RMB53,868,000), the change in accumulated losses represents mainly the loss of the Company amounting to RMB1,184,691,000 (2017: RMB223,477,000).

The balance sheet of the Company was approved by the Board of Directors on 21 March 2019 and was signed on its behalf:

Ou Zonghong	Zeng Feiyan
# DIRECTORS’ AND CHIEF EXECUTIVE’S INTERESTS AND SHORT POSITIONS

As at 31 December 2019, the interests and short positions of the directors and the chief executive of the Company in the shares, underlying shares or debentures of the Company or any of its associated corporations (within the meaning of Part XV of the SFO) as recorded in the register kept by the Company pursuant to Section 352 of the SFO or as otherwise notified to the Company and The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) pursuant to the Model Code for Securities Transactions by Directors of Listed Issuers set out in Appendix 10 to the Rules Governing the Listing of Securities on the Stock Exchange (the “Listing Rules”) were as follow:

# (1) Long positions in the ordinary share (each a “Share”) of HK\$0.10 each in the Company

董事及最高行政人員之權益及淡倉

於二零一九年十二月三十一日，本公司董事及最高行政人員於本公司或其任何相聯法團（定義見證券及期貨條例第XV部）之股份、相關股份或債券中擁有根據證券及期貨條例第352條本公司存置之登記冊所記錄，或已根據香港聯合交易所有限公司（「聯交所」）證劵上市規則（「上市規則」）附錄十所載上市發行人董事進行證券交易的標準守則另行知會本公司及聯交所之權益及淡倉如下：

(1) 於本公司每股面值0.10港元普通股（各為一股「股份」）之好倉

Name of Director
董事姓名	Number of Shares
股份數目	Capacity/Nature of interest
身份╱權益性質	Approximate
percentage of
shareholding
股權概約百分比
(Note 1)
（附註1）
Yeung Yung
仰融	2,673,071,189
(Note 2)
（附註2）	Interest of controlled corporation
受控法團權益
68,140,000	Beneficial owner
實益擁有人
2,741,211,189
(Note 3)
（附註3）	13.47%
Huang Chunhua
黃春華	35,000,000	Beneficial owner
實益擁有人	0.17%
Wang Chuantao
王川濤	30,000,000	Beneficial owner
實益擁有人	0.15%
Liu Stephen Quan
劉泉	281,760,000
(Note 4)
（附註4）	Founder of trust
Interest of children under 18
信託創始人
未滿18歲子女之權益
10,000,000	Beneficial owner
實益擁有人
291,760,000	1.43%
Name of Director
董事姓名	Number of Shares
股份數目	Capacity/Nature of interest
身份╱權益性質	Approximate
percentage of
shareholding
股權概約百分比
(Note 1)
（附註1）
Zhu Shengliang
朱勝良	22,043,883	Beneficial owner
實益擁有人	0.11%
Li Zhengshan
李正山	26,270,000	Beneficial owner
實益擁有人	0.13%
Ting Kwok Kit, Johnny
丁國傑	3,000,000	Beneficial owner
實益擁有人	0.015%
Chen Xiao
陳曉	25,000,000	Beneficial owner
實益擁有人	0.12%
Cheng Tat Wa
鄭達華	1,300,000	Beneficial owner
實益擁有人	0.006%
Chan Sin Hang
陳善衡	500,000	Beneficial owner
實益擁有人	0.002%

Notes:

(1) The percentage of shareholding is calculated on the basis of 20,352,872,747 Shares in issue as at 31 December 2019 and did not take into account any Shares which may fall to be allotted and issued upon exercise of any subscription rights attaching to any share options granted by the Company.

(2) These Shares are held by Sun East LLC. Sun East LLC is a limited liability company incorporated in California, the US, which is owned as to (i) 35% by Dr Yeung Yung (shared commonly with his spouse under the laws of California, the US) and (ii) 65% by Mr Ma Manwai (alias Ma Manwai, Philip) and Mr Jimmy Wang (alias Wang Jian) as co-trustees for certain trusts established for the benefit of the children of Dr Yeung Yung on 30 December 2002. Dr Yeung Yung (as well as his spouse) was deemed to be interested in the Shares held by Sun East LLC by virtue of Part XV of the SFO.

(3) The spouse of Dr Yeung Yung is deemed to be interested in the Shares beneficially held by Dr Yeung Yung by virtue of Part XV of the SFO.

(4) These Shares were indirectly owned by certain trusts of which Mr Liu Stephen Quan were the founder. The children of Mr Liu were eligible beneficiaries of the trusts. Mr Liu was deemed to be interested in these Shares by virtue of Part XV of the SFO.

附註：

(1) 持股百分比按於二零一九年十二月三十一日已發行20,352,872,747股股份計算，並無計及可能因本公司已授出之任何購股權所附任何認購權獲行使而須配發及發行之任何股份。

(2) 該等股份由Sun East LLC持有。Sun East LLC乃於美國加州註冊成立之有限公司，由(i)仰融博士擁有35%權益（根據美國加州法例與其配偶共同持有）及(ii)馬文偉先生及王健先生作為若干信託之共同信託人擁有65%權益，而該等信託於二零零二年十二月三十日設立，以仰融博士之子女為受益人。根據證券及期貨條例第XV部，仰融博士（及其配偶）被視為於Sun East LLC所持股份中擁有權益。

(3) 根據證券及期貨條例第XV部，仰融博士之配偶被視為於仰融博士實益持有之股份中擁有權益。

(4) 該等股份由劉泉先生為創始人之若干信託間接擁有。劉先生之子女為有關信託之合資格受益人。根據證券及期貨條例第XV部，劉先生被視為於該等股份中擁有權益。
Product name
(reference drugs/targets)	Indications	Progress as at the Latest
Practicable Date
Smooth progress of domestic clinical projects
HLX10+ HLX07	head and neck
squamous cell
carcinoma (HNSCC)	In July 2020, the first patient dosing
was comlpeted in a hipase 2 clincal trial
in mainland China
HLX10+ HLX04	Solid tumor	In September 2020, the enrollment of
subjects was comlpeted in a hpase 1
clinical trial
HLX10+ HLX04	Hepatocellular
Carcinoma (HCC)	In January 2021, the enrollment of
subjects was comlpeted in a hpase 2
clinical trial
HLX10+HLX04	Metastatic colorectal
cancer (mCRC)	In March 2021, the first patient dosing
was comlpeted in a Phase 2/3 clinical
trial in mainland China
HLX55 (innovative anti-c-Met
monoclonal antibody)	Solid tumor	In March 2020, the first patient dosing
was comlpeted in a hilpase 1 clinca trial
in Taiwan, China
HLX07 (modified innovative
anti-EGFR monoclonal
antibody)	Solid tumor	In March 2020, the relevant clinical
research report was comlpeted for the
h1ilpase clinical tra
HLX11 (pertuzumab)	Breast cancer (BC)	In September 2020, the first patient
dosing was comlpeted in a hpase 1
clinical trial in mainland China
HLX14 (desumumab)	Osteoporosis (OP)	In November 2020, the first patient
dosinlg was competed in a hpase 1
clinical trial in mainland China
Product name
(reference drugs/targets)	Indications	Progress as at the Latest
Practicable Date
Efficient advancement on IND aliippcaton for pre-clinical development projects
HLX13 (iilipmumab)	Melanoma, Renal Cell
Carcinoma (RCC),
Metastatic Colorectal
Cancer (mCRC)	In January 2020, the investigational new
drug alipcatipon (IND) was accepted by
the NMPA
In April 2020, the investigational new
drug alippcation (IND) was approved by
the NMPA
HLX56 (anti-DR4 monoclonal
antibody)	Solid tumor	In May 2020, the investigational new
drulg aippcation ( IND) was approved
by the Ministry of Health and Welfare
of Taiwan.
HLX70 (anti-S1 fully human
monoclonal
neutralizing antibody)	COVID-19	In October 2020, the investigational
new druiNDg alppcation (I) was
approved by the U.S. Food and Drug
Administration (FDA)
HLX71 (ACE2-Fc receptor
fusion protein)	COVID-19	In November 2020, the investigational
new druiNg alppcation (ID) was
approved by the U.S. Food and Drug
Administration (FDA)
HLX15 (daratumumab)	Multillpe myeoma
(MM)	In November 2020, the investigational
new drulg aippcation (IND) was
accepted by the NMPA
In January 2021, the investigational new
drug alippcation (IND) was approved by
the NMPA
HLX26 (Recombinant anti-
LAG-3 human
monoclonal antibody
injection)	Solid tumor, lymhpoma	In January 2021, the investigational new
drug alippcation (IND) was accepted by
the NMPA
Aspect	KPI	Content	Chapter Reference or Notes
B5.4	Description of practices used to
promote environmentally preferable
p r o d u c t s a n d s e r v i c e s w h e n
selecting suppliers, and how they are
implemented and monitored.	6.2 Responsible Procurement
B6 Product
Responsibility	General Disclosure	Information on:
(a) the policies; and
(b) compliance with relevant laws
and regulations that have
a significant impact on the
issuer
r e l a t i n g t o h e a l t h a n d s a f e t y,
advertising, labelling and privacy
matters relating to products and
services provided and methods of
redress.	6.1 Quality Guarantee
6.1.2 Customer Service
6.1.3 Information Security and Privacy
B6.1	Percentage of total products sold or
shipped subject to recalls for safety
and health reasons.	Not applicable to the Grou’ps
business
B6.2	N u m b e r o f p r o d u c t s a n d
service-related complaints received
and how they are dealt with.	6.1.2 Customer Service
B6.3	Description of practices relating to
observing and protecting intellectual
property rights.	6.1.3 Information Security and Privacy
B6.4	Description of quality assurance
process and recall procedures.	6.1.1 Safe Power Supply
Recalling procedures are not
applicable to the Grou’ps business
B6.5	Description of consumer data
protection and privacy policies, how
they are implemented and monitored.	6.1 Quality Guarantee
6.1.2 Customer Service
6.1.3 Information Security and Privacy
# 10. Content Index of the Environmental, Social and Governance Reporting Guide

Aspect	KPI	Content	Chapter Reference or Notes
B7 Anti-corruption	General Disclosure	Information on:
(a) the policies; and
(b) compliance with relevant laws
and regulations that have
a significant impact on the
issuer
relating to bribery, extortion, fraud
and money laundering.	6.3 Anti-corruption
B7.1	Number of concluded legal cases
regarding corrupt practices brought
against the issuer or its employees
during the reporting period and the
outcomes of the cases.	6.3 Anti-corruption
B7.2	Description of preventive measures
and whistle-blowing procedures, how
they are implemented and monitored.	6.3 Anti-corruption
B7.3	Description of anti-corruption training
provided to directors and staff.	6.3 Anti-corruption
B8 Community
Investment	General Disclosure	Policies on community engagement
to understand the needs of the
communities where the issuer
operates and to ensure its activities
t a k e i n t o c o n s i d e r a t i o n t h e
communities' interests.	9. Giving Back to Society
9.1 Fighting Icy Weather and
Protecting Electricity Power
9.2 Power Protection for College
Entrance Examination
9.3 Caring for the Community
B8.1	Focus areas of contribution (e.g.
education, environmental concerns,
labour needs, health, culture, sport).	9. Giving Back to Society
9.1 Fighting Icy Weather and
Protecting Electricity Power
9.2 Power Protection for College
Entrance Examination
9.3 Caring for the Community
B8.2	Resources contributed (e.g. money or
time) to the focus area.	9. Giving Back to Society
9.1 Fighting Icy Weather and
Protecting Electricity Power
9.2 Power Protection for College
Entrance Examination
9.3 Caring for the Community
“Non-competition Undertaking”	the non-competition undertaking dated 18 November
2016 igven by each of our Controlling Shareholders in
favour of our Company, details of which are set forth in
the section headed “Relationship with our Controlling
Shareholders” in this prospectus
“Placing”	the conditional lhpacinfg bhy te Underwriters o te
Placing Shares for cash at the Placing Price lpus
brokerage of 1%, SFC transaction levy of 0.0027% and
Stock Exchange trading fee of 0.005%, details of which
are described in the section headed “Structure and
conditions of the lacing” in thips prospectus on and
subject to the terms and conditions stated herein and in
the Underwriting Agreement
“Placing Price”	the l0pacini2Plig prce of HK$. hper acnSig are (excludng
brokerage, Stock Exchange trading fee and SFC
transaction levy)
“Placing Shares”	the 250,000,000 new Shares being offered for
subscription by our Company at the Placing Price under
the Placing
“PRC Legal Advisers”	Dentons Law Offices, the Com’panys legal advisers as to
the PRC law
“Reorganisation”	the corporate reorganisation of our Group in preparation
for the Listing as described in the sections headed
“History, reorganisation and group structure” in this
prospectus
“RMB”	Renminbi, the lawful currency of the PRC
“SFC”	the Securities and Futures Commission of Hong Kong
“SFO”	Securities and Futures Ordinance (Chapter 571 of the
Laws of Hong Kong), as amended, sulppemented or
otherwise modified from time to time
“Share(s)”	ordinary shares with a nominal value of HK$0.01 each in
the share caiptal of our Company, which are to be traded
in Hong Kong dollars and listed on GEM
“Shareholder(s)”	holder(s) of the Shares